

### COVID-19 IMPACT

This report has been affected by the COVID-19 pandemic. All forecasts and analysis have been revised to reflect the current view including the effect of the pandemic and associated recession.

# RESEARCH REPORT



## COMPANION DIAGNOSTIC MARKETS

### THE FUTURE OF DIAGNOSTICS

BY FUNDING SOURCE AND APPLICATION WITH CUSTOMIZED  
FORECASTING/ANALYSIS, COVID UPDATES,  
AND EXECUTIVE AND CONSULTANT GUIDES  
2021-2025



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

## Table of Contents

i. Companion Diagnostic Market - Strategic Situation Analysis .....	19
ii. Guide for Executives, Marketing, Sales and Business Development Staff .....	22
iii. Guide for Management Consultants and Investment Advisors .....	24
1. Introduction and Market Definition .....	25
1.1 What are Companion Diagnostics? .....	26
1.2 The Personalized Medicine Revolution .....	29
1.3 Market Definition .....	31
1.3.1 Revenue Market Size .....	31
1.4 Methodology .....	32
1.4.1 Authors .....	32
1.4.2 Sources .....	33
1.5 A Spending Perspective on Clinical Laboratory Testing .....	34
1.5.1 U.S. Medicare Expenditures for Laboratory Testing .....	34
2. Market Overview .....	36
2.1 Players in a Dynamic Market .....	37
2.1.1 Academic Research Lab .....	38
2.1.2 Diagnostic Test Developer .....	38
2.1.3 Instrumentation Supplier .....	38
2.1.4 Distributor and Reagent Supplier .....	39
2.1.5 Independent Testing Lab.....	39

2.1.6 Public National/regional lab .....	40
2.1.7 Hospital lab .....	40
2.1.8 Physician Office Labs .....	41
2.1.9 Audit Body .....	41
2.1.10 Certification Body.....	42
2.2 Personalized Medicine and Companion Diagnostics .....	43
2.2.1 Basics .....	43
2.2.2 Method.....	44
2.2.3 Disease risk assessment .....	44
2.2.4 Applications.....	44
2.2.5 Diagnosis and intervention .....	45
2.2.5.1 Companion Diagnostics .....	46
2.2.6 Drug development and usage .....	46
2.2.7 Respiratory proteomics .....	47
2.2.8 Cancer genomics .....	48
2.2.9 Population screening .....	49
2.2.10 Challenges.....	49
2.2.11 Regulatory oversight .....	49
2.2.12 Intellectual property rights.....	50
2.2.13 Reimbursement policies.....	50
2.2.14 Patient privacy and confidentiality .....	50
2.3 Chromosomes, Genes and Epigenetics .....	52
2.3.1 Chromosomes.....	52
2.3.2 Genes .....	54

2.3.3 Epigenetics .....	57
2.4 Cancer Genes .....	58
2.4.1 Germline vs Somatic .....	60
2.4.2 Changing Clinical Role .....	62
2.5 Structure of Industry Plays a Part .....	63
2.5.1 New Pharmaceutical Funding Market .....	63
2.5.2 Economies of Scale .....	63
2.5.2.1 Hospital vs. Central Lab .....	64
2.5.3 Physician Office Labs .....	65
2.5.4 Physicians and POCT.....	65
3. Market Trends.....	67
3.1 Factors Driving Growth.....	68
3.1.1 Level of Care .....	68
3.1.2 Immuno-oncology.....	69
3.1.3 Liability .....	69
3.1.4 Aging Population.....	69
3.2 Factors Limiting Growth.....	71
3.2.1 State of knowledge .....	71
3.2.2 Genetic Blizzard.....	72
3.2.3 Protocol Resistance.....	72
3.2.4 Regulation and coverage .....	72
3.3 Instrumentation and Automation.....	73
3.3.1 Instruments Key to Market Share .....	73
3.3.2 Bioinformatics Plays a Role .....	73

3.4 Diagnostic Technology Development .....	74
3.4.1 Next Generation Sequencing Fuels a Revolution.....	75
3.4.2 Single Cell Genomics Changes the Picture .....	76
3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment .....	77
3.4.4 CGES Testing, A Brave New World .....	77
3.4.5 Biochips/Giant magneto resistance based assay .....	78
4. Companion Diagnostics Recent Developments .....	79
4.1 Recent Developments – Importance and How to Use This Section .....	80
4.1.1 Importance of These Developments .....	80
4.1.2 How to Use This Section.....	80
Biocartis Collaborating with Endpoint Health on CDx Tests for Idylla Platform .....	80
FDA Approves Foundation Medicine Liquid Biopsy Test as CDx for Three Targeted Therapies .....	82
Promega to Develop MSI Assay as CDx.....	87
HTG Molecular Q2 Revenues Drop 66 Percent .....	88
Guardant Health to Develop CDx for Janssen .....	90
Burning Rock Bio, CStone Pharmaceuticals to Codevelop CDx.....	90
FDA Approval for FoundationOne®CDx .....	91
FDA finalizes CDx Guidance .....	92
QIAGEN Launches CDx Therascreen BRAF Test .....	93
Myriad Genetics Seeks Approval for Companion Diagnostic.....	94
ARUP Labs Seek PMA for Hemophilia Gene Therapy CDx.....	95
QIAGEN Builds on Global Collaboration with Amgen.....	96
Foundation Medicine nabs 19th companion Dx.....	96

Maze Therapeutics Uses CRISPR for Precision Medicine Companion Diagnostics .....	97
Myriad Wins Japanese Approval for BRACAnalysis.....	100
Fujitsu Improves Efficiency in Cancer Genomic Medicine .....	101
Thermo Fisher's automated sequencer to offer same-day, pan-cancer test results .....	103
Takeda, Prometheus Enter IBD Drug-Companion Diagnostic Partnership .....	104
Thermo Fisher, Eli Lilly Ink CDx Collaboration in NSCLC, Thyroid Cancer .....	105
Roche VENTANA PD-L1 (SP142) Assay approved as companion diagnostic.....	107
Universal Genetic Testing for All Breast Cancer Patients.....	108
Exact Sciences buys Genomic Health.....	109
Biodesix Highlights Pipeline and Companion Diagnostic Development .....	111
Multi-Gene Liquid Biopsy Breast Cancer Panel.....	113
New Gene Panel Identifies High Risk Prostate Cancer .....	113
Guardant Health Liquid Biopsy Test to be Covered by EviCore.....	115
Inivata Completes £39.8M Series B Funding Round.....	116
Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance.....	116
CellMax, Medigen Biotech Partner in Colorectal Cancer Clinical Trials .....	117
5. Profiles of Key Players .....	119
10x Genomics, Inc.....	120
Abbott Diagnostics.....	121
AccuraGen Inc.....	123
Adaptive Biotechnologies .....	124
Aethlon Medical.....	126
Agena Bioscience, Inc.....	127
Agilent .....	129



Anchor Dx .....	131
ANGLE plc .....	132
ApoCell, Inc. ....	133
ArcherDx, Inc. ....	134
ARUP Laboratories .....	135
Asuragen.....	137
AVIVA Biosciences .....	139
Baylor Miraca Genetics Laboratories .....	140
Beckman Coulter, Inc. ....	141
Becton, Dickinson and Company.....	142
BGI Genomics Co. Ltd .....	144
Bioarray Genetics .....	146
Biocartis .....	147
Biocept, Inc.....	148
Biodesix Inc. ....	149
BioFluidica .....	150
BioIVT .....	153
Biolidics Ltd.....	154
bioMérieux Diagnostics .....	155
Bioneer Corporation.....	157
Bio-Rad Laboratories, Inc.....	159
Bio-Reference Laboratories .....	161
Bio-Techne .....	162
Bioview .....	164

Bolidics.....	166
Boreal Genomics.....	167
Bristol-Myers Squibb.....	168
Cancer Genetics.....	170
Caris Molecular Diagnostics.....	172
Castle Biosciences, Inc. ....	173
CellMax Life.....	174
Cepheid (now Danaher).....	175
Charles River Laboratories.....	177
Chronix Biomedical.....	179
Circulogene.....	180
Clinical Genomics.....	181
Cynvenio.....	183
Cytolumina Technologies Corp. ....	184
CytoTrack.....	185
Datar Cancer Genetics Limited.....	186
Diagnologix LLC.....	187
Diasorin S.p.A. ....	189
Enzo Life Sciences, Inc. ....	190
Epic Sciences.....	192
Epigenomics AG.....	193
Eurofins Scientific.....	194
Exosome Diagnostics.....	197
Exosome Sciences.....	199

Fabric Genomics .....	200
Fluidigm Corp .....	201
Fluxion Biosciences .....	202
Foundation Medicine (now Roche) .....	203
Freenome .....	204
FUJIFILM Wako Diagnostics .....	205
GeneFirst Ltd. ....	206
Genetron Health (Beijing) Co., Ltd.....	207
Genomic Health .....	208
GenomOncology .....	210
GILUPI Nanomedizin .....	211
Grail, Inc. ....	212
Guardant Health .....	214
HalioDx .....	215
HansaBiomed .....	216
HeiScreen .....	217
Helomics .....	218
Horizon Discovery .....	220
HTG Molecular Diagnostics.....	222
iCellate .....	224
Illumina .....	225
Incell Dx.....	226
Inivata.....	227
Integrated Diagnostics.....	228

Invivogen .....	229
Invivoscribe .....	230
Janssen Diagnostics .....	231
MDNA Life SCIENCES, Inc.....	232
MDx Health .....	233
Menarini Silicon Biosystems .....	234
Miltenyi Biotec.....	236
MIODx.....	237
miR Scientific .....	238
Molecular MD .....	239
MyCartis .....	240
Myriad Genetics/Myriad RBM .....	241
NantHealth, Inc. ....	243
Natera .....	245
NeoGenomics .....	247
New Oncology .....	249
Novogene Bioinformatics Technology Co., Ltd. ....	250
Oncocyte.....	252
OncoDNA.....	253
Ortho Clinical Diagnostics .....	254
Oxford Nanopore Technologies.....	255
Panagene .....	257
Perkin Elmer.....	258
Personal Genome Diagnostics.....	260

Personalis.....	261
Precipio .....	262
PrecisionMed .....	263
Promega .....	264
Qiagen Gmbh .....	266
Rarecells SAS.....	268
RareCyte .....	270
Roche Molecular Diagnostics .....	271
ScreenCell .....	273
Sense Biodetection. ....	274
Serametrix .....	275
Siemens Healthineers .....	276
Silicon Biosystems.....	278
simfo GmbH .....	279
Singlera Genomics Inc. ....	280
Singulomics .....	281
SkylineDx.....	283
Stratos Genomics .....	284
Systemx Inostics.....	285
Tempus Labs, Inc. ....	286
Thermo Fisher Scientific Inc. ....	287
Thrive Earlier Detection .....	289
Todos Medical .....	290
Trovagene.....	291

Volition.....	292
Vortex Biosciences .....	293
6. The Global Market for Companion Diagnostics.....	294
6.1 Global Market Overview by Country.....	295
6.1.1 Table – Global Market by Country.....	295
6.1.2 Chart - Global Market by Country .....	296
6.2 Global Market by Application - Overview .....	297
6.2.1 Table – Global Market by Application .....	297
6.2.2 Chart – Global Market by Application – Base/Final Year Comparison .....	298
6.2.3 Chart – Global Market by Application – Base Year .....	299
6.2.4 Chart – Global Market by Application – Final Year.....	300
6.2.5 Chart – Global Market by Application – Share by Year.....	301
6.3 Global Market Funding Source - Overview .....	302
6.3.1 Table – Global Market by Funding Source .....	302
6.3.2 Chart – Global Market Funding Source – Base/Final Year Comparison .....	303
6.3.3 Chart – Global Market Funding Source – Base Year .....	304
6.3.4 Chart – Global Market Funding Source – Final Year.....	305
6.3.5 Chart – Global Market Funding Source – Share by Year .....	306
7. Global Companion Diagnostic Markets – By Application .....	307
7.1 Oncology .....	308
7.1.1 Table Oncology – by Country .....	308
7.1.2 Chart - Oncology Growth.....	309
7.2 Neurology.....	310
7.2.1 Table Neurology – by Country.....	310

7.2.2 Chart - Neurology Growth .....	311
7.3 Cardiology .....	312
7.3.1 Table Cardiology – by Country .....	312
7.3.2 Chart - Cardiology Growth.....	313
7.4 Other Application.....	314
7.4.1 Table Other Application – by Country.....	314
7.4.2 Chart - Other Application Growth .....	315
8. Global Companion Diagnostic Markets – Funding Source.....	316
8.1 Global Market Pharmaceutical .....	317
8.1.1 Table Pharmaceutical – by Country.....	317
8.1.2 Chart - Pharmaceutical Growth .....	318
8.2 Global Market Venture .....	319
8.2.1 Table Venture – by Country.....	319
8.2.2 Chart - Venture Growth .....	320
8.3 Global Market Clinical .....	321
8.3.1 Table Clinical – by Country.....	321
8.3.2 Chart - Clinical Growth .....	322
8.4 Global Market Other Funding .....	323
8.4.1 Table Other Funding – by Country.....	323
8.4.2 Chart - Other Funding Growth .....	324
Appendices .....	325
I. United States Medicare System: January 2020 Clinical Laboratory Fees Schedule .....	325
II. Pharmacogenomic Biomarkers in Drug Labeling .....	399

## Table of Tables

Table 1 Lab Spending 2014 to 2024 .....	35
Table 2 Market Players by Type .....	37
Table 3 The Base Pairs.....	55
Table 4 Five Factors Driving Growth .....	68
Table 5 Four Factors Limiting Growth .....	71
Table 6 Key Diagnostic Laboratory Technology Trends .....	74
Table 7 Next Generation Sequencing Technologies – Speed and Cost .....	75
Table 8 Global Companion Diagnostic Market by Region.....	295
Table 9 Global Market by Application .....	297
Table 10 Global Market by Funding Source .....	302
Table 11 Oncology by Country .....	308
Table 12 Neurology by Country.....	310
Table 13 Cardiology by Country .....	312
Table 14 Other Application by Country.....	314
Table 15 Pharmaceutical by Country .....	317
Table 16 Venture by Country .....	319
Table 17 Clinical by Country .....	321
Table 18 Other Funding by Country .....	323
Table 19 Pharmacogenomic Biomarkers .....	399



## Table of Figures

Figure 1 FDA Approved Companion Diagnostics.....	28
Figure 2 Clinical Lab Spending 2014 to 2024 .....	35
Figure 3 DNA Strands and Chromosomes .....	52
Figure 4 Karyogram of Human Chromosomes .....	53
Figure 5 Size of Various Genomes .....	56
Figure 6 Germline vs Somatic Mutations.....	60
Figure 7 Comparing Genomic Diagnostic and Traditional Testing .....	62
Figure 8 Percentage of World Population Over 65.....	70
Figure 9 Base Year Country Market Share Chart .....	296
Figure 10 CDx Market by Application - Base vs. Final Year .....	298
Figure 11 CDx Market by Application Base Year .....	299
Figure 12 CDx Market by Application Final Year.....	300
Figure 13 Application Type Share by Year.....	301
Figure 14 Funding Source – Base vs. Final Year .....	303
Figure 15 Funding Source Market Base Year .....	304
Figure 16 Funding Source Market Final Year .....	305
Figure 17 Funding Source Share by Year .....	306
Figure 18 Oncology Growth .....	309
Figure 19 Neurology Growth.....	311
Figure 20 Cardiology Growth .....	313
Figure 21 Other Application Growth.....	315

Figure 22 Pharmaceutical Growth ..... 318

Figure 23 Venture Growth ..... 320

Figure 24 Clinical Growth ..... 322

Figure 25 Other Funding Growth ..... 324

Figure 26 2020 Clinical Laboratory Fee Schedule ..... 325